Text Size

Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease

Labetoulle, M.; Benitez-del-Castillo, J. M.; Barabino, S.; Herrero Vanrell, R.; Daull, P.; Garrigue, J.-S.; Rolando, M.

  • 2022
  • International journal of molecular sciences
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Affiliations

    Service d’Ophtalmologie, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, 94270 Le Kremlin Bicêtre, France; Department of Ophthalmology, Hospital Clinico de Madrid, Universidad Complutense, 28040 Madrid, Spain; Centro Superficie Oculare e Occhio Secco, ASST Fatebenefratelli-Sacco, Ospedale L. Sacco, Università di Milano, 20157 Milan, Italy; Research Group (UCM 920415), Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal), Faculty of Pharmacy, Complutense University, 28040 Madrid, Spain; Ophthalmic Innovation Center, Santen SAS, 91058 Evry, France; Ocular Surface Centre, ISPRE (Instituto di Medicina Oftalmica) Ophthalmic, 16129 Genoa, Italy

Related Publications

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis

Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, Amrane M, Ismail D, Doan S, Bremond-Gignac D.

Correlation between gene expression and clinical scores in vernal keratoconjunctivitis

Leonardi A, Cavarzeran F, Rosani U, Righetti G, Garrigue JS, Brun P.

Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials

Leonardi A, Doan S, Aragona P,  Amrane M, Ismail D, Montero J, Németh J, Bremond-Gignac D

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022